HealthcareLAUNCHLaunched
Lupin launched Formoflo-G MDI triple-combination inhaler for COPD in India
Hyderabad, Telangana7 Oct 2026
Lupin launched Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler for moderate to severe COPD in India, following approval from the Drug Controller General of India (DCGI). The inhaler combines glycopyrronium bromide, formoterol fumarate and fluticasone propionate and is available as a twice-daily, single-strength fixed dose, the company said.
Why it matters
A DCGI-approved triple-therapy inhaler product launch expands available treatment options for COPD patients in India in a single-device regimen.
LupinDrug Controller General of India (DCGI)